HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SR 8278

structure in first source

Also Known As:

SR-8278; SR8278

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - SR 8278: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - SR 8278: 5
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - SR 8278: 5

Experts

1.	Choe, Han Kyoung: 2 articles (07/2022 - 01/2022)
2.	Choe, Youngshik: 2 articles (07/2022 - 01/2022)
3.	Choi, Ji-Woong: 2 articles (07/2022 - 01/2022)
4.	Choi, Mijung: 2 articles (07/2022 - 01/2022)
5.	Jang, Sangwon: 2 articles (07/2022 - 01/2022)
6.	Kim, Doyeon: 2 articles (07/2022 - 01/2022)
7.	Kim, Jeongah: 2 articles (07/2022 - 01/2022)
8.	Kim, Kyungjin: 2 articles (07/2022 - 01/2022)
9.	Moon, Cheil: 2 articles (07/2022 - 01/2022)
10.	Park, Inah: 2 articles (07/2022 - 01/2022)

Related Diseases

1.	Mood Disorders (Mood Disorder) 01/01/2022 - "These results indicate that REV-ERBα is a potential therapeutic target, and its antagonist, SR8278, is a potential drug for mood disorders related to circadian disturbances, namely sundowning syndrome, in Parkinson's disease." 07/01/2022 - "Correction to: Pharmacological Rescue With SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist As A Therapy for Mood Disorders In Parkinson's Disease." 01/01/2022 - "Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease."
2.	Parkinson Disease (Parkinson's Disease) 01/01/2022 - "These results indicate that REV-ERBα is a potential therapeutic target, and its antagonist, SR8278, is a potential drug for mood disorders related to circadian disturbances, namely sundowning syndrome, in Parkinson's disease." 07/01/2022 - "Correction to: Pharmacological Rescue With SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist As A Therapy for Mood Disorders In Parkinson's Disease." 01/01/2022 - "Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease."
3.	Infections 10/23/2023 - "We found that treatment with the circadian-enhancing agents nobiletin and SR8278 reduced infection of herpes simplex virus 1 in epidermal explants and human keratinocytes in a BMAL1/CLOCK-dependent manner. " 04/18/2023 - "We found that treatment of circadian enhancing agents, nobiletin and SR8278, reduced infection of herpes simplex virus 1 (HSV1) in epidermal explants and human keratinocytes in a Bmal1/Clock-dependent manner. "
4.	Muscular Dystrophies (Muscular Dystrophy) 12/07/2017 - "Therefore, we decided to explore whether the REV-ERB antagonist SR8278 could slow the progression of muscular dystrophy. "
5.	Fibrosis (Cirrhosis) 12/07/2017 - "In mdx mice SR8278 increased lean mass and muscle function, and decreased muscle fibrosis and muscle protein degradation. "

Related Drugs and Biologics

1.	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)
2.	nobiletin
3.	Muscle Proteins (Muscle Protein)

Related Therapies and Procedures

1.	Therapeutics